A fixed dose combination of tenofovir disoproxil fumarate, lamivudine and efavirenz. It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and adolescents (from 12 years of age and weighing ≥ 40 kg) with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months.